Article
The Acid Ceramidase Is a SARS-CoV-2 Host Factor
15 Aug 2022
Abstract excerpt
SARS-CoV-2 variants such as the delta or omicron variants, with higher transmission rates, accelerated the global COVID-19 pandemic. Thus, novel therapeutic strategies need to be deployed. The inhibition of acid sphingomyelinase (ASM), interfering with viral entry by fluoxetine was reported. Here, we described the acid ceramidase as an additional target of fluoxetine. To discover these effects, we synthesized an...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
